Products for Research Use Only

Bretylium (tosylate)

CAT: 0804-HY-12961A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12961A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bretylium (tosylate) is an inhibitor of the presynaptic release of vasoconstrictor neurotransmitters. It is the sympathetic nerve and adrenergic ganglion blocking agent . (1) Bretylium tosylate inhibits adrenergic function presynaptically only after an initial release in neurotransmitter substance. (2) The reference for administration dose is 15 mg/kg (I.P) .
CAS Number
61-75-6
UNSPSC
12352005
Hazard Statement
H302+H312+H332
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Bretylium-tosylate.html
Concentration
10mM
Purity
99.90
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[N+](C)(CC)CC1=CC=CC=C1Br.O=S(C2=CC=C(C)C=C2)([O-])=O
Molecular Formula
C18H24BrNO3S
Molecular Weight
414.36
Precautions
H302+H312+H332
References & Citations
[1]McGinn R et al. Adenosine receptor inhibition attenuates the suppression of postexercise cutaneous blood flow. J Physiol. 2014 Jun 15;592 (12) :2667-78.|[2]Tew GA et al. Aging and aerobic fitness affect the contribution of noradrenergic sympathetic nerves to the rapid cutaneous vasodilator response to local heating. J Appl Physiol (1985) . 2011 May;110 (5) :1264-70|[3]Cakir B et al.Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers. Physiol Res. 2007;56 (3) :315-22. Epub 2006 Jun 22.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched